Market Cap 254.54M
Revenue (ttm) 794,000.00
Net Income (ttm) -37.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 120,100
Avg Vol 73,805
Day's Range N/A - N/A
Shares Out 19.55M
Stochastic %K 41%
Beta 1.52
Analysts Strong Sell
Price Target $44.25

Company Profile

Crescent Biopharma, Inc. operates as a biotechnology company dedicated to advancing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors. The company was incorporated in 2024 and is based in USA.

Industry: Biotechnology
Sector: Healthcare
Address:
United States
TwongStocks
TwongStocks Jul. 16 at 10:43 PM
One month post-RS recap. $GCTK 1:60 RS on Jun 16, closed $6.30 Announced diabetes data on Jun 25, which sent the stock spiking to $15.90. Wasn't able to hold & went back down. Today closed $5.345, down 15.16% from RS close. $NCI 1:5 RS on Jun 16, closed $1.89 Able to stay above its closing price on Jun 16. Reached its peak on Jun 20 at $2.98. Today closed $2.11, up 11.64% from RS close. $CBIO 1:100 RS on Jun 16, closed $15.80 This RS was part of a merger with GlycoMimetics. Reached its peak on Jun 25 at $21.98. Held fairly steady for a while, closing around $15-$16. Howveer, has recently started closing below $13. Today closed $13.14, down 16.84% from RS close.
1 · Reply
BiotechDrTrader
BiotechDrTrader Jul. 16 at 4:53 PM
$CBIO All the best biotech venture capital firms in the world have put their money into CBIO as a fast follower to SMMT. They aren't stupid, so I expect once enough accumulation happens here it will re-rate higher. Might take some time though...
0 · Reply
slick3333
slick3333 Jul. 15 at 6:49 PM
$CBIO nice dump after PT analysis of $28 think they met .28
0 · Reply
Wallstreetiscriminal
Wallstreetiscriminal Jul. 14 at 10:17 PM
$CBIO Took my loss and got out @ 19. The whole merger and immediate RS was some shady dealing where the former GLYC folks got robbed. Lucky for the post merger pump, but now we can truly see where this is going. Phase 1 trial in the middle of next year? Folks you’re probably looking at 2-3 rounds of dilution before they get through phase 3. Price of this is way inflated for where they are at!
0 · Reply
JarvisFlow
JarvisFlow Jul. 14 at 1:01 PM
Wedbush updates rating for Crescent Biopharma ( $CBIO ) to Outperform, target set at 27.
0 · Reply
slick3333
slick3333 Jul. 11 at 9:25 PM
$CBIO ought
0 · Reply
Magic8BallResponse
Magic8BallResponse Jul. 1 at 6:51 PM
$CBIO why bother! $SMMT all the way!
0 · Reply
Chemist_Without_Limits
Chemist_Without_Limits Jun. 27 at 10:17 PM
$CBIO Why don't CBIO and GLYC track identically after the merger? Are there still two different stocks for sale?
0 · Reply
MorenitaScorp
MorenitaScorp Jun. 26 at 2:04 PM
$CBIO ⌚️
0 · Reply
JarvisFlow
JarvisFlow Jun. 25 at 2:54 PM
Stifel has adjusted their stance on Crescent Biopharma ( $CBIO ), setting the rating to Buy with a target price of 28.
0 · Reply
Latest News on CBIO
Crescent Biopharma Appoints David Lubner to Board of Directors

Apr 28, 2025, 7:30 AM EDT - 2 months ago

Crescent Biopharma Appoints David Lubner to Board of Directors


GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

May 9, 2024, 3:17 PM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript


GlycoMimetics: Is No News Bad News?

Apr 30, 2024, 7:42 AM EDT - 1 year ago

GlycoMimetics: Is No News Bad News?


GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 10:27 AM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript


GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 21, 2024, 5:47 PM EDT - 1 year ago

GlycoMimetics Can Become A Game Changer In Blood Cancers


GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

Nov 3, 2023, 12:24 PM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript


GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 1:09 PM EDT - 2 years ago

GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Call Transcript


TwongStocks
TwongStocks Jul. 16 at 10:43 PM
One month post-RS recap. $GCTK 1:60 RS on Jun 16, closed $6.30 Announced diabetes data on Jun 25, which sent the stock spiking to $15.90. Wasn't able to hold & went back down. Today closed $5.345, down 15.16% from RS close. $NCI 1:5 RS on Jun 16, closed $1.89 Able to stay above its closing price on Jun 16. Reached its peak on Jun 20 at $2.98. Today closed $2.11, up 11.64% from RS close. $CBIO 1:100 RS on Jun 16, closed $15.80 This RS was part of a merger with GlycoMimetics. Reached its peak on Jun 25 at $21.98. Held fairly steady for a while, closing around $15-$16. Howveer, has recently started closing below $13. Today closed $13.14, down 16.84% from RS close.
1 · Reply
BiotechDrTrader
BiotechDrTrader Jul. 16 at 4:53 PM
$CBIO All the best biotech venture capital firms in the world have put their money into CBIO as a fast follower to SMMT. They aren't stupid, so I expect once enough accumulation happens here it will re-rate higher. Might take some time though...
0 · Reply
slick3333
slick3333 Jul. 15 at 6:49 PM
$CBIO nice dump after PT analysis of $28 think they met .28
0 · Reply
Wallstreetiscriminal
Wallstreetiscriminal Jul. 14 at 10:17 PM
$CBIO Took my loss and got out @ 19. The whole merger and immediate RS was some shady dealing where the former GLYC folks got robbed. Lucky for the post merger pump, but now we can truly see where this is going. Phase 1 trial in the middle of next year? Folks you’re probably looking at 2-3 rounds of dilution before they get through phase 3. Price of this is way inflated for where they are at!
0 · Reply
JarvisFlow
JarvisFlow Jul. 14 at 1:01 PM
Wedbush updates rating for Crescent Biopharma ( $CBIO ) to Outperform, target set at 27.
0 · Reply
slick3333
slick3333 Jul. 11 at 9:25 PM
$CBIO ought
0 · Reply
Magic8BallResponse
Magic8BallResponse Jul. 1 at 6:51 PM
$CBIO why bother! $SMMT all the way!
0 · Reply
Chemist_Without_Limits
Chemist_Without_Limits Jun. 27 at 10:17 PM
$CBIO Why don't CBIO and GLYC track identically after the merger? Are there still two different stocks for sale?
0 · Reply
MorenitaScorp
MorenitaScorp Jun. 26 at 2:04 PM
$CBIO ⌚️
0 · Reply
JarvisFlow
JarvisFlow Jun. 25 at 2:54 PM
Stifel has adjusted their stance on Crescent Biopharma ( $CBIO ), setting the rating to Buy with a target price of 28.
0 · Reply
TCEnterprises
TCEnterprises Jun. 24 at 11:52 AM
0 · Reply
topstockalerts
topstockalerts Jun. 24 at 11:50 AM
Pre Market Top Gainers $NA $INM $IBIO $CBIO $NKTR
0 · Reply
topstockalerts
topstockalerts Jun. 24 at 10:37 AM
Pre Market Top Gainers $IBIO $CBIO $NKTR $GIBO $PSTV
0 · Reply
Wallstreetiscriminal
Wallstreetiscriminal Jun. 23 at 6:21 PM
$CBIO $CAPR Still no one looking at CBIO? It’s up almost 40% +5.79 today and no comments on it? Wish I had more shares. First time I’ve been involved in a RS that returns me over 75% in a week. Big things brewing just like CAPR. And a super low float. Went up $5.89 ~40% on only 24k shares traded!
1 · Reply
Archie126
Archie126 Jun. 23 at 6:02 PM
$CBIO boom...something's cooking!
1 · Reply
RollingDollars
RollingDollars Jun. 23 at 5:59 PM
0 · Reply
RollingDollars
RollingDollars Jun. 23 at 5:59 PM
0 · Reply
Wallstreetiscriminal
Wallstreetiscriminal Jun. 23 at 4:47 PM
$CAPR Were getting approved!! In the meantime $CBIO is blowing up hard. Up 32% up almost $5 today and no one’s talking about it! Shrooms are the future along with everything that CAPR has brewing. No stress from shrooms and if you do have heart issues from stress CAPR has your remedy!!
0 · Reply
jmorris48
jmorris48 Jun. 20 at 3:59 PM
0 · Reply
StockScanners
StockScanners Jun. 20 at 4:06 AM
$CBIO Keep watch if this holds above 12.75
0 · Reply
YasirTrades
YasirTrades Jun. 19 at 6:22 PM
GLMD Opportunities like this don’t come often but they only shine early when the real ones speak up…. $VTAK $PRSO $INBS $CBIO
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 18 at 9:33 PM
$CBIO completes merger with GlycoMimetics and secures $200M financing. Lead program CR-001 (PD-1 x VEGF bispecific) on track for IND submission Q4 2025. Shares now trade as CBIO with cash runway through 2027. High-risk/high-reward play in competitive immuno-oncology space. https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/tm2518203d1_8k.htm
0 · Reply